Nexalin Technology Enhances Advisory Board for Alzheimer’s Research
Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW), a pioneer in Deep Intracranial Frequency Stimulation (DIFS™), is committed to addressing the growing challenges faced by individuals with Alzheimer’s disease. By reconstituting its Scientific Advisory Board (SAB) with leading experts in neurology, neuroimaging, and neurodegenerative diseases, Nexalin aims to strengthen its Alzheimer’s-focused initiatives. This strategic move comes amidst positive findings from both published studies and internal data related to its proprietary DIFS™ technology.
Introducing New Experts to the Board
The newly appointed board members include Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer. Each expert brings with them a wealth of knowledge and specialized skills that are crucial for driving forward Nexalin’s ambitious research agenda. The restructured advisory board will significantly influence the scientific direction and clinical strategies concerning neurodegenerative and neuropsychiatric disorders.
Mark White, CEO of Nexalin Technology, emphasized the importance of this enhanced advisory board: "The appointment of Drs. Huang, Owens, and Scheer underscores our commitment to advancing our Alzheimer's disease initiatives. Their high-caliber expertise is indispensable as we navigate the complexities of clinical trials aimed at addressing the pressing public health challenge of Alzheimer's disease."
Innovative Technology Driving Progress
Nexalin’s Gen-2 SYNC and Gen-3 Halo™ headset utilize DIFS™, which effectively addresses cognitive decline by targeting deeper areas of the brain. Recent encouraging data has shown that this proprietary waveform may enhance neuroplasticity and aid in the functional recovery of areas responsible for memory and executive functioning. These insights have prompted Nexalin to intensify its research efforts related to Alzheimer’s disease, with the advisory board’s restructuring providing the required guidance for innovative trial designs and biomarker assessments.
Expert Profiles on the SAB
Dr. Mingxiong Huang is renowned for his work in magnetoencephalography (MEG) and neuroimaging. With over 25 years of experience, he serves as a Professor of Radiology at the University of California, San Diego. His contributions to MEG source imaging have significantly advanced the understanding of various neurological conditions.
Dr. Abe Scheer joins the board with an impressive four-decade career in both adult and pediatric neurology and psychiatry. He brings valuable insights from his past roles at prestigious institutions and will help propel Nexalin's commitment to innovative, non-invasive treatment options.
Dr. David Owens, serving as Chief Medical Officer, has over 25 years of experience specializing in neuroradiology. He has made significant contributions to clinical research emphasizing interventional therapies for neurological disorders, enhancing the scope of Nexalin’s initiatives.
Looking Ahead: Clinical Trials and Advancements
As Nexalin moves forward, new clinical studies focused on Alzheimer’s will be initiated soon, which will incorporate cognitive testing, imaging biomarkers, and metrics guided by MEG technology. The expertise of the SAB will be vital in ensuring laws and regulations guide these studies, helping to evaluate the efficacy of treatments and their implications on neural activation.
Dr. Scheer remarked on this innovative approach, stating, "Nexalin’s technology embodies a pioneering method of brain modulation that may potentially improve therapeutic efficacy over traditional pharmacological treatments, especially in the early stages of the disease.”
Commitment to Mental Health Solutions
The restructuring of the SAB highlights Nexalin's continuous evolution as a science-oriented firm focused on revolutionizing mental health and therapeutic solutions for neurodegenerative diseases. By leveraging advanced bioelectronic medicine, Nexalin aspires to significantly impact care delivery for patients dealing with mental health challenges.
About Nexalin Technology, Inc.
Nexalin Technology is dedicated to designing and developing state-of-the-art neurostimulation products aimed at combating the pressing global mental health crisis. With all its products being non-invasive and undetectable, Nexalin strives to provide relief for individuals facing various mental health disorders. By engaging bioelectronic medical technology, the company believes its devices can penetrate deeper into critical brain structures leading to improved patient outcomes without adverse side effects. The Nexalin Gen-2 neurostimulation device has garnered approval across multiple countries, including China and Brazil.
Frequently Asked Questions
What is Nexalin Technology's primary focus?
Nexalin Technology primarily focuses on developing neurostimulation products aimed at addressing mental health issues, particularly Alzheimer’s disease.
Who are the new members of Nexalin's Scientific Advisory Board?
The new members include Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each bringing significant expertise in their respective fields.
What technology does Nexalin use for its treatments?
Nexalin employs Deep Intracranial Frequency Stimulation (DIFS™) technology to target cognitive decline and neurodegenerative disorders.
When are the new clinical studies set to begin?
The company plans to initiate new Alzheimer’s-focused clinical studies in the upcoming third quarter.
How does Nexalin believe its technology can benefit patients?
Nexalin's technology is believed to offer non-pharmacological alternatives that may enhance treatment efficacy for Alzheimer’s patients, focusing on innovative approaches to brain health.
